Newsfeeds - Spark Newswire

1 minute read

Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate

Today, 6:06 PM

Provention Bio Inc (NASDAQ:PRVB) has entered into a co-promotion agreement with Sanofi SA (NASDAQ:SNY) to launch Provention’s lead investigational candidate, teplizumab, to delay…

PRVB

1 minute read

Jefferies Initiates Coverage On Provention Bio with Buy Rating, Announces Price Target of $10

By Benzinga Newsdesk

Today, 6:06 PM

Jefferies analyst Chris Howerton initiates coverage on Provention Bio (NASDAQ:PRVB) with a Buy rating and announces Price Target of $10.

PRVB

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

Today, 6:06 PM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

3 minute read

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

By Vandana Singh

Today, 6:06 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADCT

1 minute read

Provention Bio Announced $60M Private Placement of Common Stock and Warrants to Acquire 13,318,535 Additional Shares of Its Common Stock

By Charles Gross

Today, 6:06 PM

Provention Bio, Inc.

PRVB

3 minute read

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

By Vandana Singh

Today, 6:06 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AKBA

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 6:06 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Provention Bio’s Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months

By Vandana Singh

Today, 6:06 PM

Provention Bio Inc (NASDAQ: PRVB) announced

PRVB

1 minute read

Provention Bio Announces FDA Acceptance Of The Biologics License Application Resubmission For Teplizumab For The Delay Of Clinical Type 1 Diabetes In At-Risk Individuals

By Benzinga Newsdesk

Today, 6:06 PM

Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the resubmitted Biologics License

PRVB

3 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 6:06 PM

CLOV